Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MAP2K1 D67N NRAS G12C PTEN del |
| Therapy | Copanlisib + Sotorasib |
| Indication/Tumor Type | T-cell acute lymphoblastic leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MAP2K1 D67N NRAS G12C PTEN del | T-cell acute lymphoblastic leukemia | sensitive | Copanlisib + Sotorasib | Preclinical - Cell culture | Actionable | In a preclinical study, Lumakras (sotorasib) and Aliqopa (copanlisib) synergistically inhibited viability in a T-cell acute lymphoblastic leukemia cell line harboring NRAS G12C, MAP2K1 D67N, and PTEN deletion in culture (PMID: 41340466). | 41340466 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (41340466) | Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer. | Full reference... |